Trial Profile
A Phase I/II Proof of Concept, Open-Label, Repeat Dose, Dose Escalation Study of NM-002 in Adult Patients With Short Bowel Syndrome (SBS)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 07 Nov 2022
Price :
$35
*
At a glance
- Drugs Vurolenatide (Primary)
- Indications Short bowel syndrome
- Focus Proof of concept; Therapeutic Use
- Sponsors 9 Meters Biopharma [CEASED]; Naia Limited
- 13 May 2021 Status changed from active, no longer recruiting to completed, according to a 9 Meters Biopharma media release.
- 22 Mar 2021 According to a 9 Meters Biopharma media release, companys R and D day on 23rd Mar 2021 to include additional study data on parenteral support, pharmacokinetics and quality of life.
- 07 Dec 2020 Results published in a 9 Meters Biopharma media release.